Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Tick-Borne Nairoviruses Use OTU Proteases to Evade Human Antiviral Signals

Published

on

Summer is peak tick season, and with it comes familiar threats like Lyme disease and Rocky Mountain spotted fever. But scientists say another group of tick‑borne pathogens is quietly gaining ground: nairoviruses, a diverse family of negative‑sense RNA viruses carried by ticks across Asia, Europe, Africa—and now the western United States. Several nairoviruses can infect humans, causing high fevers, severe headaches, and, in some cases, organ dysfunction. One member of the family, Crimean‑Congo hemorrhagic fever virus (CCHFV), is often fatal and considered a global‑level threat.

Nairoviruses are found in ticks that feed on wildlife, livestock, and people. Recent human infections have been documented in China and Japan, including Songling virus (SGLV), Tacheng tick virus 1 (TTV1), and Yezo virus (YEZV). A related virus, Beiji virus (BJNV), caused an outbreak involving more than 100 patients in northeastern China. And on the U.S. West Coast, researchers recently identified Pacific Coast Tick nairovirus (PCTNV) in Dermacentor occidentalis, a tick already known to transmit Rocky Mountain spotted fever. As the paper noted, “Pacific Coast Tick nairovirus… was recently identified in Mendocino, California, from tick species known to harbor human pathogens and having a large presence across the state.”

The new study, titled “Insights into the Structure and Function of the OTU Protease Virulence Factors from Emerging Human Nairoviruses,” was published in ACS Infectious Diseases and reveals how these emerging viruses may slip past human immune defenses. All orthonairoviruses encode a specialized enzyme called ovarian tumor protease (OTU), which can remove small protein tags—ubiquitin and ISG15—from human proteins. Those tags normally act as alarm signals that activate immune responses, and removing them effectively evades the immune system. As the paper explained, “OTUs exhibit varying levels of deubiquitinating (DUB) and deISGylating activities that facilitate viral immune evasion, establishing them as key virulence factors.”

In the work, researchers isolated OTU proteases from four emerging nairoviruses—SGLV, TTV1, YEZV, and PCTNV—and compared their ability to strip immune‑signaling proteins. The standout was PCTNV, whose enzyme showed the strongest ability to remove both ubiquitin and ISG15. That suggests PCTNV may be unusually adept at evading human immunity, raising concerns because the virus is carried by a human‑biting tick common along the Pacific Coast.

The team also resolved high‑resolution crystal structures of several OTU proteases. These structural insights allowed the researchers to train computational models that begin to predict which nairoviruses may pose the greatest threat. “The biochemical and structural insights provide a path forward for predicting OTU activity among current and emerging nairoviruses,” the authors wrote.

Such predictive tools could help public‑health agencies monitor new tick‑borne viruses before they spread widely. As corresponding author Scott D. Pegan, PhD, of the University of California, Riverside, noted, “This study reinforces the need to be vigilant about not just tick bites but the type of ticks that an individual has been bitten by, as they may carry diseases beyond what we have been used to looking for.”

The post Tick-Borne Nairoviruses Use OTU Proteases to Evade Human Antiviral Signals appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read